So Invivo are issued consideration shares at 21.5 cents each but shareholders were asked to pay 23 cents.
As stated earlier this acquisition is turning out to be a huge cost to longer term shareholders. The share price is now down 50% from when they announced the acquisition.
The company is being run by bankers and scientists. Not a good mix.
Hopefully the quarterly will be more positive than the previous quarterlies.
Ann: Application for quotation of securities - MAP, page-2
Add MAP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $80.61M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 18.0¢ | 17.5¢ | $17.99K | 102.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35882 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 100000 | 1 |
View Market Depth
| Last trade - 12.44pm 20/06/2024 (20 minute delay) ? |
| MAP (ASX) Chart |